577 related articles for article (PubMed ID: 16530901)
1. A classification framework and practical guidance for establishing a mode of action for chemical carcinogens.
Butterworth BE
Regul Toxicol Pharmacol; 2006 Jun; 45(1):9-23. PubMed ID: 16530901
[TBL] [Abstract][Full Text] [Related]
2. An evaluation of the mode of action framework for mutagenic carcinogens case study: Cyclophosphamide.
McCarroll N; Keshava N; Cimino M; Chu M; Dearfield K; Keshava C; Kligerman A; Owen R; Protzel A; Putzrath R; Schoeny R
Environ Mol Mutagen; 2008 Mar; 49(2):117-31. PubMed ID: 18240158
[TBL] [Abstract][Full Text] [Related]
3. A strategy for establishing mode of action of chemical carcinogens as a guide for approaches to risk assessments.
Butterworth BE; Conolly RB; Morgan KT
Cancer Lett; 1995 Jun; 93(1):129-46. PubMed ID: 7600540
[TBL] [Abstract][Full Text] [Related]
4. Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?
Gaylor DW
Regul Toxicol Pharmacol; 2005 Mar; 41(2):128-33. PubMed ID: 15698536
[TBL] [Abstract][Full Text] [Related]
5. Strategy for genotoxicity testing: hazard identification and risk assessment in relation to in vitro testing.
Thybaud V; Aardema M; Clements J; Dearfield K; Galloway S; Hayashi M; Jacobson-Kram D; Kirkland D; MacGregor JT; Marzin D; Ohyama W; Schuler M; Suzuki H; Zeiger E;
Mutat Res; 2007 Feb; 627(1):41-58. PubMed ID: 17126066
[TBL] [Abstract][Full Text] [Related]
6. Chloroform mode of action: implications for cancer risk assessment.
Golden RJ; Holm SE; Robinson DE; Julkunen PH; Reese EA
Regul Toxicol Pharmacol; 1997 Oct; 26(2):142-55. PubMed ID: 9356278
[TBL] [Abstract][Full Text] [Related]
7. Approaches to cancer assessment in EPA's Integrated Risk Information System.
Gehlhaus MW; Gift JS; Hogan KA; Kopylev L; Schlosser PM; Kadry AR
Toxicol Appl Pharmacol; 2011 Jul; 254(2):170-80. PubMed ID: 21034767
[TBL] [Abstract][Full Text] [Related]
8. Reducing uncertainty in risk assessment by using specific knowledge to replace default options.
McClellan RO
Drug Metab Rev; 1996; 28(1-2):149-79. PubMed ID: 8744594
[TBL] [Abstract][Full Text] [Related]
9. An adjustment factor for mode-of-action uncertainty with dual-mode carcinogens: the case of naphthalene-induced nasal tumors in rats.
Bogen KT
Risk Anal; 2008 Aug; 28(4):1033-51. PubMed ID: 18564993
[TBL] [Abstract][Full Text] [Related]
10. Cancer risk assessment for 1,3-butadiene: data integration opportunities.
Preston RJ
Chem Biol Interact; 2007 Mar; 166(1-3):150-5. PubMed ID: 16647696
[TBL] [Abstract][Full Text] [Related]
11. An evaluation of the mode of action framework for mutagenic carcinogens case study II: chromium (VI).
McCarroll N; Keshava N; Chen J; Akerman G; Kligerman A; Rinde E
Environ Mol Mutagen; 2010 Mar; 51(2):89-111. PubMed ID: 19708067
[TBL] [Abstract][Full Text] [Related]
12. Children as a sensitive subpopulation for the risk assessment process.
Preston RJ
Toxicol Appl Pharmacol; 2004 Sep; 199(2):132-41. PubMed ID: 15313585
[TBL] [Abstract][Full Text] [Related]
13. IPCS framework for analyzing the relevance of a cancer mode of action for humans.
Boobis AR; Cohen SM; Dellarco V; McGregor D; Meek ME; Vickers C; Willcocks D; Farland W
Crit Rev Toxicol; 2006; 36(10):781-92. PubMed ID: 17118728
[TBL] [Abstract][Full Text] [Related]
14. Use of genetic toxicology information for risk assessment.
Dearfield KL; Moore MM
Environ Mol Mutagen; 2005 Dec; 46(4):236-45. PubMed ID: 16258925
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the human relevance of chemically induced animal tumors.
Cohen SM; Klaunig J; Meek ME; Hill RN; Pastoor T; Lehman-McKeeman L; Bucher J; Longfellow DG; Seed J; Dellarco V; Fenner-Crisp P; Patton D
Toxicol Sci; 2004 Apr; 78(2):181-6. PubMed ID: 14737005
[TBL] [Abstract][Full Text] [Related]
16. Mode-of-action framework for evaluating the relevance of rodent forestomach tumors in cancer risk assessment.
Proctor DM; Gatto NM; Hong SJ; Allamneni KP
Toxicol Sci; 2007 Aug; 98(2):313-26. PubMed ID: 17426108
[TBL] [Abstract][Full Text] [Related]
17. A comprehensive approach for integration of toxicity and cancer risk assessments.
Butterworth BE; Bogdanffy MS
Regul Toxicol Pharmacol; 1999 Feb; 29(1):23-36. PubMed ID: 10051416
[TBL] [Abstract][Full Text] [Related]
18. Carcinogenicity categorization of chemicals-new aspects to be considered in a European perspective.
Bolt HM; Foth H; Hengstler JG; Degen GH
Toxicol Lett; 2004 Jun; 151(1):29-41. PubMed ID: 15177638
[TBL] [Abstract][Full Text] [Related]
19. A proposed framework for assessing risk from less-than-lifetime exposures to carcinogens.
Felter SP; Conolly RB; Bercu JP; Bolger PM; Boobis AR; Bos PM; Carthew P; Doerrer NG; Goodman JI; Harrouk WA; Kirkland DJ; Lau SS; Llewellyn GC; Preston RJ; Schoeny R; Schnatter AR; Tritscher A; van Velsen F; Williams GM
Crit Rev Toxicol; 2011 Jul; 41(6):507-44. PubMed ID: 21591905
[TBL] [Abstract][Full Text] [Related]
20. Analysis of in vivo mutation data can inform cancer risk assessment.
Moore MM; Heflich RH; Haber LT; Allen BC; Shipp AM; Kodell RL
Regul Toxicol Pharmacol; 2008 Jul; 51(2):151-61. PubMed ID: 18321622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
